Yan Leyfman: Advancing CAR Therapy for AML
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Sascha Haubner, et al. on LinkedIn:
“Advancing CAR Therapy for AML.
Acute myeloid leukemia (AML) remains a challenging disease, especially in the relapsed/refractory (R/R) setting. While CAR T-cell therapy has transformed treatment for other leukemias, adapting it for AML presents unique hurdles, including target antigen selection and safety concerns.
Exciting innovations are now emerging, including multiantigen targeting, logic gating, and advanced cell engineering to enhance efficacy while mitigating toxicity. Strategies like pharmacologic modulation, genetic epitope engineering, and CAR on/off switches offer promising avenues to refine AML treatment.
The next wave of CAR therapies is on the horizon—bringing new hope for improved outcomes!”
Honing CAR T cells to tackle acute myeloid leukemia.
Authors: Sascha Haubner, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023